Lipocine Inc. (LPCN)

2.72
NASDAQ : Health Technology
Prev Close 2.74
Day Low/High 2.62 / 3.03
52 Wk Low/High 1.04 / 2.80
Avg Volume 110.40K
Exchange NASDAQ
Shares Outstanding 24.84M
Market Cap 68.07M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Lipocine Receives FDA Clearance For Clinical Testing Its NASH Candidate, LPCN 1144, In Expanded Target Population

Lipocine Receives FDA Clearance For Clinical Testing Its NASH Candidate, LPCN 1144, In Expanded Target Population

SALT LAKE CITY, July 23, 2019 /PRNewswire/  --  Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has received clearance from the U.

Lipocine Set To Join Russell Microcap® Index

Lipocine Set To Join Russell Microcap® Index

SALT LAKE CITY, Utah, June 25, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is set to join the Russell Microcap® Index at the conclusion...

Lipocine Announces TLANDO™ NDA PDUFA Action Date Of November 9, 2019

Lipocine Announces TLANDO™ NDA PDUFA Action Date Of November 9, 2019

SALT LAKE CITY, May 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.

Lipocine Announces First Quarter 2019 Financial And Operational Results

Lipocine Announces First Quarter 2019 Financial And Operational Results

SALT LAKE CITY, May 8, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2019, and provided a corporate update.

Lipocine Seeks Injunction Against The Marketing Of Clarus Therapeutics' JATENZO® For Testosterone Replacement Therapy

Lipocine Seeks Injunction Against The Marketing Of Clarus Therapeutics' JATENZO® For Testosterone Replacement Therapy

SALT LAKE CITY, April 3, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has filed suit against Clarus Therapeutics, Inc.

Lipocine Announces ABPM Labeling Study Results Consistent With Recently Approved Testosterone Replacement Therapy

Lipocine Announces ABPM Labeling Study Results Consistent With Recently Approved Testosterone Replacement Therapy

SALT LAKE CITY, March 27, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced findings from the Ambulatory Blood Pressure Monitoring clinical study...

Lipocine Late-Breaker Presentation At EASL Meeting To Detail LPCN 1144 MRI-PDFF Based Clinical Results On Reduction Of Liver Fat And Key Serum Biomarkers

Lipocine Late-Breaker Presentation At EASL Meeting To Detail LPCN 1144 MRI-PDFF Based Clinical Results On Reduction Of Liver Fat And Key Serum Biomarkers

SALT LAKE CITY, March 26, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today acceptance of their abstract for late-breaker presentation on LPCN 1144 clinical results as part of The International Liver...

Lipocine To Participate At The ROTH Battle Of The NASH Thrones Spring Investor Conference

Lipocine To Participate At The ROTH Battle Of The NASH Thrones Spring Investor Conference

SALT LAKE CITY, March 21, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr.

Lipocine Announces Presentation Highlighting Therapeutic Potential Of LPCN 1144 In NAFLD And NASH Selected For ENDO 2019

Lipocine Announces Presentation Highlighting Therapeutic Potential Of LPCN 1144 In NAFLD And NASH Selected For ENDO 2019

SALT LAKE CITY, March 14, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical results as part of ENDO 2019.

Lipocine's LPCN 1144 For NASH Demonstrates Substantial Fatty Liver Resolution And Meaningful Liver Fat Reduction In NAFLD Population

Lipocine's LPCN 1144 For NASH Demonstrates Substantial Fatty Liver Resolution And Meaningful Liver Fat Reduction In NAFLD Population

SALT LAKE CITY, March 12, 2019 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on endocrine and metabolic disorders, today announced top-line results from the 16-week Liver Fat Imaging Study ("Liver Fat Study")...

Lipocine To Participate At The 31st Annual ROTH Conference

Lipocine To Participate At The 31st Annual ROTH Conference

SALT LAKE CITY, March 11, 2019 /PRNewswire/ --   Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Morgan Brown, Executive Vice President and Chief Financial Officer, will provide a corporate overview to investors at...

Lipocine Announces Financial And Operational Results For The Year Ended December 31, 2018

Lipocine Announces Financial And Operational Results For The Year Ended December 31, 2018

SALT LAKE CITY, March 6, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the year ended December 31, 2018.